News

InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.

InSphero has acquired California-based PhenoVista Biosciences to expand its US presence and strengthen advanced imaging and phenotypic analysis capabilities for predictive drug discovery and safety testing.

InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.

InSphero has entered a strategic partnership with PharmaNest Inc to advance the translational assessment of fibrosis in human-relevant 3D in vitro models. By combining advanced 3D liver spheroids with high-resolution, AI-enabled digital pathology, the collaboration aims to enable quantitative, phenotype-resolved analysis of fibrotic remodeling and improve the prediction of therapeutic efficacy in complex fibrotic diseases.

European microphysiological systems (MPS) industry leaders are announcing today the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world’s first industry association dedicated to represent MPS providers.

InSphero AG has signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technologies, including the Sun Bioscience Gri3D® platform. The deal strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models for drug discovery and safety testing.

The Physicians Committee and InSphero Launch Award Program to Accelerate Adoption of Human In Vitro Models.

InSphero appoints former Evotec CEO Dr. Werner Lanthaler to its Board of Directors, strengthening its mission to scale reliable 3D in vitro drug testing solutions.

InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.

InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.

InSphero has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal assays to our global customer base.

InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.